Erythrodermic Epidermolysis Bullosa Acquisita
Epidermolysis bullosa acquisita (EBA) is a rare acquired subepidermal blistering autoimmune disease of the skin and mucosae associated with autoantibodies directed against type VII collagen, the major component of the anchoring fibrils of the dermal-epidermal junction. 1,2 Various clinical presentations of EBA have been described, including a noninflammatory mechanobullous form, an inflammatory bullous pemphigoid (BP)like form, and a mucous-membrane pemphigoid-like form. These forms may show clinical overlap, and their courses are often unpredictable. [1] [2] [3] Report of a Case | A 60-year-old man was admitted for evaluation of a 3-week history of widespread pruritic cutaneous lesions. The patient had taken no drugs, and his medical history was unre- markable. On examination, almost his entire trunk, buttocks, and thighs were erythematous and infiltrated with papular and urticarial lesions (Figure 1) . Islands of normal-appearing skin were observed. On his soles and palms, isolated lesions with a targetlike appearance were noted. The head as well as the oral and genital mucous membranes were spared. During hospital admission, the patient developed isolated vesicles and serous blisters on erythematous skin on his wrist and ankle.
Light microscopy studies of a skin biopsy specimen obtained from patient's back showed a diffuse spongiosis with a mixed perivascular inflammatory infiltrate consisting of eosinophils and neutrophils in the upper dermis ( Figure 2) . Direct immunofluorescence microscopy studies disclosed linear deposits of IgG and C3 along the epidermal basement membrane zone. By indirect immunofluorescence microscopy using sodium chloride-separated normal human skin, circulating IgG autoantibodies binding the dermal side of the split were detected.
Immunoblotting analysis using human dermal extracts showed a reactivity with a 290-kDa protein showing the same electrophoretic migration to the protein band recognized by the control monoclonal antibody directed against type VII collagen.
Based on the clinical features and immunopathological findings, the diagnosis of EBA was made. 1 The patient was given oral prednisolone, 0.75 mg/kg of body weight, which resulted in rapid clearance of the lesions within 2 weeks. Corticosteroid doses were subsequently slowly tapered. At a dose of 10 mg/d, the patient experienced a relapse and began treatment with methotrexate, 15 mg subcutaneously once weekly. The prednisolone dose was then tapered to 2.5 mg/d, and the patient remained asymptomatic at 6-month follow-up.
Discussion | The clinical features of EBA are protean. The classic presentation is that of a noninflammatory mechanobullous disease characterized by the development of acral blist e r s t h at h e a l w it h at r o p h i c s c a r r i ng , m i l i a , a n d hyperpigmentation or hypopigmentation. They are localized to trauma-prone surfaces such as elbows, knees, hands, and feet. 1-3 Acral involvement may be mutilating. Scalp involvement occurs in up to 20% of patients. 1-3 The inflammatory BP-like presentation is associated with widespread vesicles and bullae involving intertriginous and flexural areas that heal without atrophic scarring. 1-3 Epidermolysis bullosa acquisita may also present as mucous membrane pemphigoid or as Brunsting-Perry pemphigoid phenotype. 3 The potential causes of erythroderma include psoriasis, atopic dermatitis, drug reactions, and cutaneous T-cell lymphoma. With the exception of pemphigus foliaceus, the other autoimmune bullous diseases of the skin have been only anecdotally implicated as cause of erythroderma. Specifically, single cases of erythrodermic BP have been described. 4,5 Epidermolysis bullosa acquisita is potentially associated with a number of systemic diseases, including inflammatory bowel diseases, 1,3 but our patient showed no evidence of any of these. 
